UCB (OTCMKTS:UCBJY) Reaches New 12-Month Low – Here’s Why

UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Wednesday. The stock traded as low as $116.29 and last traded at $116.38, with a volume of 6770 shares. The stock had previously closed at $117.61.

Analysts Set New Price Targets

UCBJY has been the subject of a number of analyst reports. Jefferies Financial Group raised UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. Zacks Research lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 16th. Finally, Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, UCB presently has an average rating of “Moderate Buy”.

Get UCB alerts:

View Our Latest Analysis on UCB

UCB Stock Performance

The stock has a 50-day moving average of $126.53 and a 200 day moving average of $138.49. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

UCB Company Profile

(Get Free Report)

UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.

UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes.

Featured Stories

• Five stocks we like better than UCB
• 3 Healthcare Dividend Stocks Offering More Than Just Income
• AI Uncertainty Is Rising, But These 3 Chip ETFs Still Have Momentum
• Arhaus Has New Momentum—Could Other Furniture Stocks Be Next?
• Can Boxabl Turn Modular Homes Into AI Data Center Infrastructure?

Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.